肿瘤细胞治疗研究
ALL SOURCES
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia
22 例 AML（n=13）和 T-ALL（n=9）患者入组，中位年龄 63 岁（范围 31-77）。
CAR T cells: the missing piece needed to improve outcomes for children with cancer?
B 细胞急性淋巴细胞白血病 (B-ALL) 是儿童期最常见的癌症。
T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
双特异性 CAR-T 细胞疗法在晚期 B 细胞恶性肿瘤的临床试验中显示出有希望的结果。
Strategic innovations: Tackling challenges of immunotherapy in acute myeloid leukemia.
这些方法共同旨在为改善 AML 的免疫治疗结局提供新的见解。
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE i
第七届多利益相关方儿科战略论坛聚焦于针对儿童和青少年癌症的嵌合抗原受体（CAR）T 细胞。
共 5 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
